ERBB2 and gastric cancer: We explored the potential mechanisms that may contribute to the resistance to trastuzumab of HER2‐positive GC in this study by applying network pharmacology techniques, including identifying active components and targets in JPHTF, searching HER2‐positive GC action sites, constructing PPI networks, KEGG and GO analysis.